0.15
+0.02(+15.38%)
Currency In USD
| Previous Close | 0.13 |
| Open | 0.13 |
| Day High | 0.15 |
| Day Low | 0.13 |
| 52-Week High | 3.37 |
| 52-Week Low | 0.11 |
| Volume | 1,526 |
| Average Volume | 4.14M |
| Market Cap | 1.2M |
| PE | -0.08 |
| EPS | -1.94 |
| Moving Average 50 Days | 0.28 |
| Moving Average 200 Days | 0.77 |
| Change | 0.02 |
If you invested $1000 in ZyVersa Therapeutics, Inc. (ZVSA) since IPO date, it would be worth $0.04 as of September 09, 2025 at a share price of $0.15. Whereas If you bought $1000 worth of ZyVersa Therapeutics, Inc. (ZVSA) shares 2 years ago, it would be worth $3.85 as of September 09, 2025 at a share price of $0.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
GlobeNewswire Inc.
Sep 03, 2025 11:55 AM GMT
ZyVersa is developing Cholesterol Efflux Mediator™ VAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys’ filtration system. VAR 200 directly removes lipids from kidney cells, and it upregulates cholesterol trans
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
GlobeNewswire Inc.
Aug 14, 2025 11:55 AM GMT
Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney damage and disease progression.Earlier data by Kanbay et al (Eur J Clin Invest. 2022) demonstr
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
GlobeNewswire Inc.
Jul 21, 2025 11:55 AM GMT
WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory disease